Roll Over Yamanaka: Meet The Cell Therapy Company Bypassing iPSCs
Mogrify Flips Adult Cells Directly From State To State
Emerging Company Profile: Horizon Discovery’s former CEO Darrin Disley talks to Scrip about the importance of Mogrify’s revolutionary platform for converting cells into any state without the need to create stem cells and force them through evolutionary biology.
You may also be interested in...
The confluence of data science and molecular biology fuels expectations among biopharma industry leaders for another year of breakthrough innovation in human therapeutics. More than 70 executives and experts reveal what they are most excited about on the technology front.
Biopharma executives see value-based pricing as an increasingly important topic for the sector in 2023, while the US Inflation Reduction Act will have a major impact on portfolio strategies.
Headwinds of political instability, violent conflict, inflation and recession accompany us into 2023. Scrip surveyed industry leaders on the impacts for biopharma.